Navigate the Curis CRIS Stock Research Pages
Introduction - general company overview, financials, pipeline snapshot, upcoming catalysts
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
ERIVEDGE (vismodegib) - FDA-approved Hedgehog inhibitor partnered with Roche/Genentech for cancer
CUDC-101 - Phase 1 multi-targeted cancer drug candidate
Debio0932 - Phase 1/2 HSP90 inhibitor partnered with Debiopharm for oncology
ERIVEDGE (vismodegib)
- Developed by Curis and licensed to Genentech/Roche
- Approved in US January 2012 for advanced basal cell carcinoma (BCC)
- Roche 3q2012 earnings call: ~$19m sales total since launch
- All slides below from March 2012 investor presentation slide deck
March 2012
March and April 2012
|
|
April 2012
April 2012
|
March and April 2012
April 2012
|
